1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: During the three months ended June 30, 2025, none of our directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
+Added: During the three months ended September 30, 2025, none of our directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
Number Exhibit Description Filed
8 unchanged sentences
10/02/2025 001-38319
−Removed: Consent and Waiver under, the Voting and Support Agreement, dated April 28, 2025, by and among the Registrant and certain stockholders of Akoya Biosciences, Inc.
−Removed: named therein.
−Removed: 8-K 04/29/2025 001-38319
−Removed: 10.2* Voting and Support Agreement, dated April 28, 2025, by and among the Registrant and certain stockholders of Akoya Biosciences, Inc.
−Removed: named therein.
−Removed: 8-K 04/29/2025 001-38319
−Removed: 10.3 Securities Purchase Agreement between the Registrant and Akoya Biosciences, Inc.
−Removed: dated April 2, 2025.
−Removed: 8-K 04/04/2025 001-38319
−Removed: 10.3.1 Form of Convertible Note
−Removed: 8-K 04/04/2025 001-38319
−Removed: 10.3.2 Form of Registration Rights Agreement
−Removed: 8-K 04/04/2025 001-38319
−Removed: 10.3.3 Form of Subordination Agreement
−Removed: 8-K 04/04/2025 001-38319
−Removed: 10.4 Amendment No.
−Removed: 1, dated April 28 , 2025, to the Securities Purchase Agreement between the Registrant and Akoya Biosciences, Inc.
−Removed: dated April 2, 2025.
−Removed: 8-K 04/29/2025 001-38319
−Removed: Third Amendment to Supply and Manufacturing Agreement , entered into on June 17, 2025 and effective as of January 1 , 20 25 , between the Registrant and STRATEC SE
+Added: Akoya Biosciences , Inc.
+Added: 2021 Equity Incentive Plan and form of stock option agreement thereunder
+Added: 04/12/2021 333-254760
+Added: A koya Biosciences, Inc.
+Added: Form of Indemnification Agreement
+Added: 12/13/2024 001-40344
+Added: Exclusivity (Equity) Agreement , dated November 17, 2015, by and between Akoya Biosciences, Inc.
+Added: and The Board of Trustees of the Leland Stanford Junior University
+Added: 03/26/2021 333-254760
+Added: A mendment No.
+Added: 1 to the License Agreement, dated November 18, 2016, by and between Akoya Biosciences, Inc.
+Added: and the Boar d of Trustees of the Leland Stanford junior University
+Added: 03/26/2021 333-254760
+Added: L icense and Roy alty Agreement, dated September 28, 2028, by and among Akoya Biosciences, Inc., Perkin Elmer Health Services, Inc., Cambridge Research and Instrumentation, Inc., and VisEn Medical Inc.
+Added: 03/26/2021 333-254760
+Added: E xclusive Patent License A g reement, dated June 26, 2018, by and between Akoya Biosciences, Inc.
+Added: and the University of Washington
+Added: 03/26/2021 333-254760
+Added: 10.7 Cooperation Agreement, by and between Quanterix Corporation, Kent Lake PR LLC and Kent Lake Partners LP, dated August 4, 2025
+Added: 8/4/2025 001-38319
31.1 Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any exhibits or schedules so furnished.
−Removed: Portions of this document (indicated by “[***]”) have been omitted because such information is not material and is the type of information that the Registrant treats as private or confidential.
+Added: + Management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
QUANTERIX CORPORATION
−Removed: August 7, 2025
+Added: November 10, 2025
/s/ Masoud Toloue, Ph.D.
2 unchanged sentences
(principal executive officer)
−Removed: August 7, 2025
+Added: November 10, 2025
/s/ Vandana Sriram
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.